PD-1 Inhibitor Bests Chemo for Colorectal Cancer
Unknown authors
Abstract
Findings from the KEYNOTE-177 study indicate that pembrolizumab is superior to the current standard of care, significantly improving progression-free survival when deployed up front to treat patients with metastatic DNA mismatch repair/microsatellite instability-high colorectal cancer.
Topics & Concepts
Microsatellite instabilityPembrolizumabColorectal cancerDNA mismatch repairMedicineCancerOncologyInternal medicineCancer researchStandard of careMicrosatelliteBiologyImmunotherapyGeneticsGeneAlleleGenetic factors in colorectal cancerCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies